Zhejiang Doer Biologics has announced the successful dosing completion of the initial participant in their Phase Ib 12-week Multiple-Ascending Dose (MAD) trial for DR10624.
This first-in-class (FIC) compound functions as a tri-specific agonist, targeting Glucagon-like peptide-1 receptor (GLP-1R), Glucagon receptor (GCGR), and Fibroblast growth factor 21 receptor (FGF21R). The study's primary focus is evaluating DR10624's potential for treating obesity and hypertriglyceridemia in New Zealand.
The Phase I MAD (Multiple Ascending Dose) study is a clinical trial to investigate the safety, tolerability, pharmacokinetics (how the drug moves within the body), and pharmacodynamics (how the drug interacts with the body) of DR10624.
DR10624 is a novel FIC tri-specific biotherapeutic designed to selectively activate three distinct receptors: GLP-1R (Glucagon-Like Peptide-1 Receptor), GCGR (Glucagon Receptor), and FGF21R (Fibroblast Growth Factor 21 Receptor). The proprietary MultipleBody® platform technology developed by Doer Bio enables to exhibit balanced activity for metabolic diseases.
In preclinical investigations, DR10624 consistently exhibited favourable outcomes, including reductions in body weight, improved glucose levels, enhanced metabolic function, and better liver functionality.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!